ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 9, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 9, 2010
News
Pfizer Names New Head; PhRMA Appoints New Chairman
By Patricia Van Arnum
Pfizer (New York) appointed Ian C. Read, currently head of the company's global biopharmaceutical operations, as president, chief executive officer, and director. He succeeds Jeffrey B. Kindler, who retired from the company.
PDUFA Discussions Continue, New Review Models Proposed
By Angie Drakulich
The US Food and Drug Administration posted on its website the minutes of the latest meetings between the agency and industry, and among stakeholders, regarding the reauthorization of the Prescription Drug User Fee Act V.
China and India to Be World Leaders of Innovation
By Stephanie Sutton
China and India will become the world leaders in innovation during the next decade, according to an international survey released by AstraZeneca.
Sanofi Withdraws Emerflu Application
By Stephanie Sutton
Sanofi Pasteur has formally withdrawn its application to the European Medicines Agency (EMA) for a centralized marketing authorization for its pandemic influenza vaccine Emerflu.
Week of Dec. 6, 2010: Company and People Notes: GlaxoSmithKline Acquires Nanjing MeiRui Pharma; Cephalon's CEO to Remain on Medical Leave; and More.
Company and People Notes: GlaxoSmithKline acquires Nanjing MeiRui Pharma; Cephalon's CEO to remain on medical leave; and more.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here